Lilly showcases positive late-stage data in diabetes treatments
pharmafile | June 13, 2016 | News story | Research and Development, Sales and Marketing | diabetes, lilly
Eli Lilly (NYSE: LLY) has presented data on their diabetes drugs in late-stage trials at the 76th American Diabetes Association Scientific Sessions in New Orleands, with Trulicity (dulaglutide) and Tradjenta (linagliptin) providing the pick of the results.
In the Phase III AWARD-9 trial, Trulicity significantly reduces haemoglobin A1c and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks compared to placebo plus insulin glargine. After 28 weeks of treatment with Trulicity, patients also saw significant reductions in fasting serum glucose levels while also taking less units of insulin glargine while also on Trulicity compared to the placebo plus insulin glargine patients.
Zvonko Milicevic, senior medical fellow at Lilly Diabetes, says: “Despite best efforts to manage their A1C with diet and oral agents, many people with type 2 diabetes transition to injectable therapy as a natural part of the disease progression. For people with type 2 diabetes who are inadequately controlled on insulin glargine alone, AWARD-9 may show that Trulicity is a treatment option that could significantly reduce A1c when used in combination with their current insulin therapy.”
Lilly also announced post-marketing data for Tradjenta, which launched in the US in 2015. Co-marketed by Boehringer Ingelheim, new data shows that the drug reduced blood sugar in adults with type-2 diabetes who are at risk for kidney impairment.
In the MARLINA-T2D trial at 24 weeks, Tradjenta was associated with a significant 0.6 reductio in the blood glucose measure A1c versus plaebo.
Principal trial investigator, Professor Per-Henrik Groop, comments: “Up to half of people with type 2 diabetes experience long-term problems with kidney function. Diabetes treatment options are generally limited for this group. These results support the use of Tradjenta, with just one dose for all patients, including those with type 2 diabetes who have early signs of kidney disease.”
Sean Murray
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
AOTI diabetic foot care therapy to be used by NHS
Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in …
Recce Pharmaceuticals reports positive phase 2 data for skin infection drug
Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE …
